Bial and Medis to enter partnership on CNS treatments
pharmafile | July 20, 2021 | News story | Manufacturing and Production, Sales and Marketing |
BIAL and Medis have entered into an exclusive partnership on two of Bial’s proprietary drugs: its Parkinson’s treatment Ongentys (opicapone) and epilepsy treatment Zebinix (eslicarbazepine acetate).
The partnership comprises an exclusive distribution agreement for Zebinix in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys) in 12 CEE countries (Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, North Macedonia, Serbia, Slovakia, and Slovenia.)
António Portela, Chief Executive Officer of Bial, said: “We are pleased to have Medis as our new partner.
“We believe this partnership is another important step for the extensive commercialisation of our innovative medicines. Medis shares our long-term vision and we look forward to bringing these important treatment options to patients in the CEE region.”
Martina Perharic, Medis’s Chief Executive Officer, said: “In Medis we are excited and proud to partner with BIAL and thus being able to provide two medicines which we firmly believe represent a much-needed relief to thousands of people in the region who suffer from Parkinson’s disease and epilepsy.”
Epilepsy has a high prevalence with six million people affected in Europe and 15 million Europeans estimated to experience a seizure at some time in their life.
Parkinson’s disease is a chronic, progressive neurodegenerative disorder characterised by a strong reduction of the neurotransmitter dopamine, caused by the degeneration of certain neurons in the brain.
The European Parkinson’s Disease Association (EPDA) estimates that approximately 1.2 million people in Europe suffer from this disease.
Lilly Subbotin
